Category | New cases | Retreatment cases | All cases | |||
---|---|---|---|---|---|---|
N (%) | 95 % CI | N (%) | 95 % CI | N (%) | 95 % CI | |
Total patients | N = 160 | N = 24 | N = 184 | |||
Any Resistance | 56 (35 %) | 27.61–42.39 | 5 (20.8) | 4.56–37.04 | 61 (33.1) | 26.3–39.3 |
Any Resistance to: | ||||||
STR | 10 (6.25) | 2.5–10.0 | 3 (12.5) | 0.73–25.73 | 13 (7.1) | 3.39–10.81 |
INH | 40 (25) | 18.29–31.71 | 4 (20) | 4.0–36.0 | 44 (23.9) | 17.74–30.06 |
RIF | 10 (6.25) | 2.5–10.0 | 2 (8.3) | 2.74–19.34 | 12 (6.5) | 2.94–10.06 |
EMB | 21 (13) | 7.87–18.33 | 4 (16.7) | 1.78–31.62 | 25 (13.6) | 8.65–18.55 |
Mono Resistance to | ||||||
STR | 4 (2.5) | 0.08–4. 92 | 0 (0) | - | 4 (2.2) | 0.08–4.32 |
INH | 25 (15.6) | 9.98–21.22 | 0 (0) | - | 25 (13.6) | 8.65–18.55 |
RIF | 1 (0.63) | 0.6–1.86 | 0 (0) | - | 1 (0.5) | 0.52–1.52 |
EMB | 10 (6.25) | 2.5–10.0 | 1 (4.16) | 3.83–12.15 | 11 (6.0) | 2.57–9.43 |
INH + RIF Resistant (MDR) | ||||||
INH + RIF only | 4 (2.5) | 0.08–4.92 | 0 (0) | - | 4 (2.2) | 0.08–4.32 |
INH + RIF + EMB | 1 (0.63) | 0.6–1.86 | 0 (0) | - | 1 (0.5) | 0.52–1.52 |
INH + RIF + STR | 0 (0) | 0 (0) | - | 0 (0) | - | |
INH + RIF + EMB + STR | 2 (1.25) | 0.47–2.97 | 2 (8.3) | 2.74–19.34 | 4 (2.2) | 0.08–4.32 |
Total MDR | 7 (4.4) | 1.22–7.58 | 2 (8.3) | 2.74–19.34 | 9 (4.9) | 1.78–8.02 |
INH + other Resistance | ||||||
INH + STR | 3 (1.9) | 0.22–4.02 | 1 (4.16) | 3.83–12.15 | 4 (2.2) | 0.08–4.32 |
INH + EMB | 5 (3.1) | 0.41–5.79 | 1 (4.16) | 3.83–12.15 | 6 (3.3) | 0.72–5.88 |
INH + STR + EMB | 1 (0.63) | 0.6–1.86 | 0 (0) | - | 1 (0.5) | 0.52–1.52 |
RIF + other Resistance | ||||||
RIF + EMB | 1 (0.63) | 0.6–1.86 | 0 (0) | - | 1 (0.5) | 0.52–1.52 |
RIF + STR + EMB | 1 (0.63) | 0.6–1.86 | 0 (0) | - | 1 (0.5) | 0.52–1.52 |